Akanocure is a drug development company specializing in creating novel small molecules aimed at addressing orphan and unmet needs in oncology. The company leverages an innovative chemistry platform to advance drug discovery and development processes, focusing on therapeutic approaches that block metastatic processes—the spread of cancer to surrounding tissues and distant organs, which is responsible for 90% of cancer deaths. Akanocure collaborates with industry leaders, academia, and government to integrate chemical methodologies with classic drug discovery expertise. This collaborative culture enables the company to develop drugs that can significantly impact the lives of cancer patients.

Akanocure serves clients in the pharmaceutical and biotechnology sectors, particularly those focused on oncology. The company operates in the highly specialized market of cancer treatment, targeting niche areas where there is a significant unmet medical need. Its business model revolves around the research and development of proprietary drug candidates, which are then licensed or sold to larger pharmaceutical companies for further development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.

Keywords: Oncology, Drug Development, Small Molecules, Metastasis, Cancer Treatment, Innovative Chemistry, Orphan Diseases, Pharmaceutical Collaboration, Biotechnology, Therapeutic Approaches.